Skip to main content
. 2012 Oct 10;7(10):e46022. doi: 10.1371/journal.pone.0046022

Table 1. Children's demographic characteristics, medicine type and ADR information.

ID Age1 Gender Ranked IMD scores2 Type of drug associated with suspected ADR Body system affected by suspected ADR Severity score3 Whether suspected ADR contributed to hospitalisation/prolonged inpatient stay Underlying condition by body system
A1 3–5 Female 403 Antibiotics Skin and mucous membranes 3 Yes (contributed towards admission) Respiratory
A2 12+ Male 10787 NSAID Musculoskeletal 3 Yes (reason for admission) Musculoskeletal
A3 3–5 Male 306 Corticosteroids, Cytotoxics Haematological 3 Yes (reason for admission) Haematological
A4 12+ Female 2482 Cytotoxics Gastrointestinal 3 Yes (reason for admission) Haematological
A5 0–2 Female 12821 Antibiotics Skin and mucous membranes 3 Yes (reason for admission) Respiratory
A6 0–2 Male 1574 Cytotoxics Haematological 3 Yes (reason for admission) Haematological
A7 0–2 Male 15485 Corticosteroids, Cytotoxics Haematological, immune system 3 Yes (reason for admission) Haematological
A8 3–5 Female 383 Vaccines Skin and mucous membrane 3 Yes (reason for admission) None
A9 6–11 Male 6091 Corticosteroids Immune 3 Yes (reason for admission) Musculoskeletal
A10 0–2 Female 12223 Vaccines Immune Infection Missing Missing Gastrointestinal
A11 6–11 Female 16778 Antibiotics Skin and mucous membranes 1 No (inpatient stay not prolonged) Musculoskeletal, nervous, respiratory, gastrointestinal, skeletal
A12 3–5 Female 271 Antiepileptic Hepatic 3 No (inpatient stay not prolonged) Musculoskeletal, nervous, gastrointestinal
A13 0–2 Male N/A Antibiotics Skin and mucous membranes 3 No (inpatient stay not prolonged) Musculoskeletal, gastrointestinal, nervous
A14 6–11 Male 19865 Opioid analgesia Nervous 3 No (inpatient stay not prolonged) Gastrointestinal
A15 12+ Female 24299 Opioid analgesia+other post-operative analgesia Nervous 3 No (inpatient stay not prolonged) Musculoskeletal
A16 0–2 Female 24447 Opioid analgesia Skin and mucous membranes 3 No (inpatient stay not prolonged) Gastrointestinal
A17 12+ Male 108 Opioid analgesia Gastrointestinal 1 No (inpatient stay not prolonged) Gastrointestinal
A18 12+ Male N/A Antibiotics Manifestation was flushing of skin but underlying cause was immune 3 No (inpatient stay not prolonged) Musculoskeletal, skin and mucous membranes, renal, gastrointestinal, metabolic
A19 0–2 Male 18461 Antibiotics Manifestation was flushing of skin but underlying cause was immune 3 No (inpatient stay not prolonged) Gastrointestinal
A20 6–11 Female 14971 Drugs used in status epilepticus Nervous 1 No (inpatient stay not prolonged) Gastrointestinal
A21 12+ Male 19823 Opioid analgesia Gastrointestinal 3 No (inpatient stay not prolonged) Musculoskeletal
A22 6–11 Male 29022 Opioid analgesia Respiratory 1 No (inpatient stay not prolonged) Musculoskeletal, nervous
A23 3–5 Male 5171 Opioid analgesia Gastrointestinal 3 No (inpatient stay not prolonged) Cardiovascular
A24 12+ Male N/A Corticosteroid Cardiovascular 5 No (inpatient stay not prolonged) Haematological
A25 6–11 Male 26028 Opioid analgesia Nervous 3 No (inpatient stay not prolonged) Musculoskeletal, nervous
A26 12+ Female 11667 Drugs affecting the cardiovascular system Nervous 3 No (inpatient stay not prolonged) Musculoskeletal, cardiovascular
A27 6–11 Female 24071 Antibiotics; Non-opioid analgesia Skin and mucous membranes 3 No (inpatient stay not prolonged) Respiratory
YC1 12+ Male 32210 Immunological products and vaccines Endocrine N/A N/A None
YC2 12+ Male 17251 Drugs used for attention deficit disorder Neurological N/A N/A Mental health
YC3 12+ Female 20387 Immunological products and vaccines Haematological N/A N/A None
YC4 12+ Male 31691 Non-opioid analgesia Renal N/A N/A None
YC5 12+ Female 20737 Immunological products and vaccines Neurological, Musculoskeletal, Gastrointestinal, Skin and mucous membranes, mental health N/A N/A None
YC6 12+ Female 31439 Immunological products and vaccines Neurological, Immune, Musculoskeletal N/A N/A None
YC7 6–11 Female N/A Respiratory Mental health N/A N/A Respiratory
YC8 12+ Female 29831 Immunological products and vaccines Musculoskeletal, Neurological N/A N/A None
YC9 6–11 Male 22922 Immunological products and vaccines Gastrointestinal N/A N/A None
YC10 12+ Female 30656 Immunological products and vaccines Neurological, Musculoskeletal, Immune N/A N/A None
YC11 0–2 Male 31508 Immunological products and vaccines Haematological N/A N/A None
YC12 12+ Female 30775 Immunological products and vaccines Immune, neurological N/A N/A None
YC13 2–6 Male 9436 Respiratory Behavioural changes N/A N/A Respiratory
YC14 2–6 Male 31612 Respiratory Behavioural changes N/A N/A Respiratory
YC15 6–11 Male 29750 Drugs used for attention deficit disorder Neurological N/A N/A Mental Health
YC16 12+ Male 25366 Insulin Behaviour changes, gastrointestinal N/A N/A Endocrine
YC17 6–11 Female 15380 Antibiotic Skin and mucous membranes N/A N/A None
1

Age reported in year groups: 0–2; 3–5; 6–11; 12 years and over.

2

Calculated using Lower Super Output Area (LSOA) 2007 ranked score data, whereby lower scores indicate greater deprivation (data for families outside England are not reported due to incompatibility between IMD scoring systems within UK).

3

Severity scores were assessed using the Hartwig scale [84] where 1 = No change in treatment with suspected drug; 2 = Drug dosing or frequency changed, without antidote or treatment for exhibited symptoms; 3 = Required treatment, or drug administration discontinued; 4 = Resulted in patient transfer to higher level of care; 5 = Caused permanent harm to patient or significant haemodynamic instability; 6 = Directly or indirectly resulted in patient death.